Literature DB >> 7418483

Volume adjustment of maximal midexpiratory flow. Importance of changes in total lung capacity.

D W Cockcroft, B A Berscheid.   

Abstract

In 21 of 100 consecutive subjects demonstrating greater than or equal to 10 percent increase in one second forced expired volume following 200 micrograms inhaled salbutamol, the forced expired flow over the middle half of the vital capacity (FEF25-75% was unchanged (n = 16) or fell greater than or equal to 10 percent (n = 5). Volume adjustment of FEF25-75%, to the same volume below total lung capacity (TLC) before and after administration of the bronchodilator resulted in significant increases in 18 of these 21 subjects. The volume-adjusted FEF25-75% increased more (98 percent) following 1500 micrograms inhaled metaproterenol in ten asthmatic subjects, and decreased more (53 percent) following inhalation of histamine in eight subjects, than did the standard FEF25-75% (44 percent increase and 34 percent decrease respectively). When the small changes in TLC which were seen following metaproterenol (4.4 +/- 4.1 percent reduction, p < 0.01) and histamine (11.0 +/- 7.2 percent increase, p < 0.001) were considered, and FEF25-75% volume adjusted so it was measured at the same absolute lung volume, greater changes were seen (198 percent increase after use of metaproterenol, and 75 percent decrease after use of histamine). When FEF25-75% is being examined following administration of a bronchodilator or a bronchoprovocation challenge, it should be volume-adjusted to absolute lung volume. When TLC cannot easily be determined repeatedly (eg routine pulmonary function studies), volume adjustment to the same volume below TLC is advised.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7418483     DOI: 10.1378/chest.78.4.595

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Lung function and health status in metropolitan fire-fighters compared to general population controls.

Authors:  Tjard Schermer; Trish Malbon; Michael Morgan; Nancy Briggs; Christine Holton; Sarah Appleton; Robbert Adams; Michael Smith; Alan Crockett
Journal:  Int Arch Occup Environ Health       Date:  2010-04-03       Impact factor: 3.015

2.  Measuring bronchodilation in COPD clinical trials.

Authors:  Z L Borrill; C M Houghton; A A Woodcock; J Vestbo; D Singh
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

3.  Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction.

Authors:  Federico Lavorini; Pietro Geri; Martina Luperini; Nazzarena M Maluccio; Laura Mariani; Cecilia Marmai; Massimo Pistolesi; Giovanni A Fontana
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

4.  Spirometry in primary care.

Authors:  Allan L Coates; Brian L Graham; Robin G McFadden; Colm McParland; Dilshad Moosa; Steeve Provencher; Jeremy Road
Journal:  Can Respir J       Date:  2013 Jan-Feb       Impact factor: 2.409

5.  The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD.

Authors:  Zoë L Borrill; Catherine M Houghton; Ruth Tal-Singer; S Rupert Vessey; Isidore Faiferman; Stephen J Langley; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

6.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.

Authors:  Brian L Graham; Irene Steenbruggen; Martin R Miller; Igor Z Barjaktarevic; Brendan G Cooper; Graham L Hall; Teal S Hallstrand; David A Kaminsky; Kevin McCarthy; Meredith C McCormack; Cristine E Oropez; Margaret Rosenfeld; Sanja Stanojevic; Maureen P Swanney; Bruce R Thompson
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.